Vestmark Advisory Solutions Inc. Sells 63,409 Shares of Intellia Therapeutics, Inc. $NTLA

Key Points

• Vestmark Advisory Solutions Inc. reduced its holdings in Intellia Therapeutics by 16.9% during the first quarter, owning 311,882 shares valued at approximately $2.22 million at the end of the quarter.
• The company's stock opened at $10.99, with a market capitalization of $1.18 billion, and a reported earnings per share of ($0.99), exceeding analyst expectations.
• Intellia Therapeutics received various ratings, including a buy rating from Chardan Capital with a target price of $60.00, while the average rating is noted as "Moderate Buy" with a consensus target price of $29.05.

Vestmark Advisory Solutions Inc. lessened its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 16.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 311,882 shares of the company's stock after selling 63,409 shares during the period. Vestmark Advisory Solutions Inc. owned approximately 0.30% of Intellia Therapeutics worth $2,217,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. ARK Investment Management LLC raised its holdings in Intellia Therapeutics by 3.8% in the 1st quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company's stock valued at $92,508,000 after acquiring an additional 474,629 shares during the last quarter. Vanguard Group Inc. lifted its stake in Intellia Therapeutics by 5.5% in the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock valued at $76,447,000 after buying an additional 561,978 shares during the last quarter. Geode Capital Management LLC grew its position in Intellia Therapeutics by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock valued at $27,865,000 after buying an additional 45,930 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of Intellia Therapeutics by 94.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock worth $23,300,000 after purchasing an additional 970,700 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Intellia Therapeutics by 36.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company's stock worth $23,042,000 after purchasing an additional 528,962 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Trading Down 0.9%

NTLA traded down $0.0880 during midday trading on Thursday, reaching $10.1220. The company's stock had a trading volume of 905,119 shares, compared to its average volume of 4,091,773. The stock has a market cap of $1.09 billion, a P/E ratio of -2.16 and a beta of 2.31. The company has a fifty day simple moving average of $11.00 and a 200 day simple moving average of $9.52. Intellia Therapeutics, Inc. has a twelve month low of $5.90 and a twelve month high of $24.16.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The company had revenue of $14.25 million for the quarter, compared to analyst estimates of $12.26 million. During the same quarter last year, the firm earned ($1.52) EPS. Intellia Therapeutics's revenue for the quarter was up 104.3% compared to the same quarter last year. Sell-side analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

NTLA has been the subject of a number of research analyst reports. Wells Fargo & Company reaffirmed an "overweight" rating and set a $45.00 price objective (down previously from $50.00) on shares of Intellia Therapeutics in a research note on Friday, August 8th. Chardan Capital dropped their target price on Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Citigroup decreased their price target on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Guggenheim reiterated a "buy" rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, August 13th. Finally, HC Wainwright reduced their price objective on Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Twelve equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $29.05.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 7,462 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total transaction of $104,617.24. Following the completion of the transaction, the executive vice president owned 106,062 shares in the company, valued at $1,486,989.24. This trade represents a 6.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 12,534 shares of company stock worth $153,837. 3.10% of the stock is currently owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.